entertainment -WSS

entertainment

author：focus 2025-10-01 17:05:59 - browse：27

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Christmas in the PICU brings some surprising joy

knowledge

WSS

CVS is on a mission to consolidate health care. Will it work?

Maisha Meds is a PBM, but don't call it that

Virtual care provider acquires bankrupt Pear's prescription apps

Hospitals owned by private equity see complications spike 25%

In Spain, a hospital brews its own CAR

Prime Medicine, Myeloid Therapeutics clash over genome

hotspot

entertainment

entertainment

Alkermes shareholders re

Christmas in the PICU brings some surprising joy

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Virginia high school admissions case could be legal follow

Violet CEO on training clinicians to promote more inclusive care

Apple is now the first public company to be valued at $3 trillion

Christmas in the PICU brings some surprising joy

Dobbs anniversary: the lost opportunity of abortion as health care

What causes osteoarthritis? Researchers study link to brain protein

hotspot

Future doctors need a strong humanities education

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

David Ricks of Eli Lilly: best biopharma CEO of 2023

Christmas in the PICU brings some surprising joy

Why health records don't always know when patients are dead

Prior authorization reform is both possible and imperative

explore

knowledge

hotspot

entertainment